tDCS for Fatigue in Sjogren's Syndrome

NCT ID: NCT04119128

Last Updated: 2020-05-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-06-03

Study Completion Date

2020-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sjogren's Syndrome (SS) is an autoimune disease of unknown etiology characterized by lymphocytic infiltration of the exocrine glands and other organs. patients usually presents with xerophthalmia, xerostomia, fatigue and other symptoms. Fatigue has often been reported as the biggest problem and the most difficult symptom patients have to deal with. Fatigue management in pSS is difficult. However, in other diseases such as Parkinson disease, post-polio syndrome and multiple sclerosis the use of Transcranial Direct Current Stimulation (tDCS) has recently been studied and has shown effectiveness. The overarching objective of this study is to examine the effect of a tDCS protocol in patients with pSS.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sjogren's Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active tDCS

Patients in this group will receive 5 active sessions of low-intensity transcranial electrical stimulation for 20 minutes.

Group Type ACTIVE_COMPARATOR

Active Transcranial Direct Current Stimulation

Intervention Type DEVICE

Subjects will undergo 5 sessions of tDCS of up to 2mA, at 20 minutes per session, 1x per day. During active stimulation, the current will be active for the full 20 minutes.

Sham tDCS

Patients in this group will receive 5 sessions of sham transcranial electrical stimulation for 20 minutes.

Group Type SHAM_COMPARATOR

Sham Transcranial Direct Current Stimulation

Intervention Type DEVICE

Subjects will undergo 5 sessions of tDCS, at 20 minutes per session, 1x per day. For sham tDCS, electrodes will be placed the same way as in the intervention group, for 20 minutes. However, the stimulator will deliver 2mA of current for only 30s. The current will not be active for the rest of the 20 minutes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Active Transcranial Direct Current Stimulation

Subjects will undergo 5 sessions of tDCS of up to 2mA, at 20 minutes per session, 1x per day. During active stimulation, the current will be active for the full 20 minutes.

Intervention Type DEVICE

Sham Transcranial Direct Current Stimulation

Subjects will undergo 5 sessions of tDCS, at 20 minutes per session, 1x per day. For sham tDCS, electrodes will be placed the same way as in the intervention group, for 20 minutes. However, the stimulator will deliver 2mA of current for only 30s. The current will not be active for the rest of the 20 minutes.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women
* Age between 18 and 65 years old;
* Diagnosis of primary Sjogren's Syndrome according to American-European Criteria;
* Stable pharmacological therapy for at least 3 months;
* Complaints of fatigue as assessed by Fatigue Severity Scale (FSS\>5).
* Complaints of fatigue for more than 3 months.

Exclusion Criteria

* Heart, coronary, respiratory, renal, or hepatic uncompensated insufficiencies;
* Uncompensated systemic arterial hypertension;
* Unable to answer the questionnaires.
* Severe depression (with a score \> 30 in the Beck Depression Inventory)
* History of epilepsy or syncope
* Implanted brain metallic devices
* Established cognitive impairment
* Traumatic brain injury with residual neurological deficits
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Pittsburgh

OTHER

Sponsor Role collaborator

Universidade Federal do Amapá

OTHER

Sponsor Role collaborator

Federal University of São Paulo

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ana Carolina Pereira Nunes Pinto

MSc

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ana Pinto, MSc

Role: PRINCIPAL_INVESTIGATOR

Federal University of Amapa/Federal University of Sao Paulo

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

FUSaoPaulo

São Paulo, São Paulo, Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FederalUnivOfSaoPaulo

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Neuromodulation in COVID-19 Patients
NCT04808284 COMPLETED PHASE1/PHASE2